Newspatrolling.com News cum Content Syndication Portal Online
Increasing excitement from industries and the demand for partnerships highlights BioAsia and Telangana’s growing role as a leading catalyst for innovation in the life sciences sector
Mumbai / Hyderabad, February 13, 2024: BioAsia, Asia’s premier life sciences and healthcare forum, is set to kick off engaging discussions enriched with profound expertise in healthcare and technology. Celebrating its 21st edition, BioAsia stands as a testament to the pioneering collaboration between the government, academia and industry, sparking innovation and driving growth in the life sciences sector.
With the significant and steady growth in the support of industry leaders around the world, BioAsia 2024 aims to establish India and Telangana as the new global innovation hub in the life sciences industry. This will be first time, the event will have five industries joining together as Principal Industry Hosts including Novartis, Dr. Reddy’s Laboratories, Bristol Meyers Squibb, Laurus Labs and Sai Lifesciences. This highlights the equal excitement and interest of Indian Multinationals and global multinationals alike to partner with the Government for BioAsia.
They will be joined by Medtronic, Aurobindo, Hetero and Aragen as Industry Co-hosts and CEO Conclave 2024 will be powered by “Rx Propellant”, which is a UK based Actis portfolio company. These collaborative effort underscores the commitment of these industry leaders to ignite and accelerate development conversations within the life sciences ecosystem.
Mr. Sridhar Babu, Minister for Industries and Commerce, Government of Telangana, expressed his enthusiasm for the partnership, stating, “BioAsia 2024 exemplifies the power of Government-Industry collaboration in driving innovation and shaping the future of the life sciences industry. Together, we are charting a course for transformative advancements that will benefit society and propel economic growth. Companies like MSN Labs, Milteyni (Germany), Citeline (UK), Garmin (US) Sartorius (Germany), Virchow Biotech, Neovantage (Singapore), Gland Pharma, Cohance (US), Bharat Biotech, Roche (Switzerland), etc have also partnered with the Government to design the sessions, contribute to knowledge sharing and ensuring the event is extremely successful.”
Mr. Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana, commented, “In today’s rapidly evolving landscape, collaboration between Government and Industry is paramount to drive innovation and foster growth. BioAsia 2024 exemplifies our commitment to fostering a vibrant ecosystem”.
BioAsia, hosted by the State Government of Telangana, is dedicated to advancing industry growth by fostering collaborations, joint ventures, and mergers and acquisitions. The event serves as a dynamic platform for companies to exhibit, launch, and showcase their unique strengths, products, and services, driving the growth of the emerging biotechnology industry.
Mr. Shakthi Nagappan, CEO of BioAsia and Director of Telangana Life Sciences, emphasized, “India’s potential to lead in integrated Life Sciences and Technology is monumental, and Telangana will continue to be a dominant player in this space. Active partnership with industry players in initiatives like BioAsia is crucial in positioning Telangana as the most attractive destination for global companies.”
BioAsia’s influence extends globally, with past editions attracting several Nobel Prize winners, Lasker Awardees, and eminent industry leaders. BioAsia 2023 witnessed participation from over 3000 global participants from 50+ countries, setting the stage for an even more impactful BioAsia 2024.
Over the years, the event has immensely benefitted from its participant history including the likes of several Nobel Prize winners, Lasker Awardees and eminent industry leaders like Mr. Bill Gates (Chair, Gates Foundation), Mr. Satya Nadella (CEO of Microsoft), Mr. Alex Gorsky (Executive Chairman, Johnson & Johnson), Dr. Vas Narasimhan (CEO, Novartis), Mr. Geoff Martha (Chairman & CEO, Medtronic), besides hosting the Country Ministers and Delegates from Asia, America, Africa, and Europe. Being the first edition post pandemic, BioAsia 2023 was extremely successful with the virtual participation of more than 3000 global participants from over 50+ Countries.
About BioAsia:
BioAsia is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders – Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policymakers, regulators, and analysts. BioAsia is focused in its efforts – to drive the growth of the industry by enabling an effective environment for fostering collaborations, JV’s M&A’s; ensure knowledge and experience sharing by global industry players to benefit all stakeholders; promote innovations and initiatives through appropriate awards and recognitions; play a pivotal role in advocating issues to the policymakers and chartering the road-map of biotechnology. BioAsia is a dynamic platform for companies -to exhibit, launch and showcase their unique strengths, products, and services. BioAsia is playing the role of a key catalyst in mobilizing all elements that are required to drive the growth of the emerging industry of Biotechnology as well as optimize the immense business potential of biotech. On a larger level, BioAsia is working to drive a global transformation from the treatment of illness to wellness.